Cheer for drugmakers as Indian court lifts ban on lots of FDC drugs

5 December 2016

Some 344 fixed dose combination (FDC) medications that have been off chemists' shelves in India for some time now, are to make a reappearance, with the Delhi High Court setting aside the Indian government’s decision to ban the FDC drugs.

The banned FDC drugs include wide-selling painkillers, anti-diabetic medicines and respiratory therapies, reports The Pharma Letter’s India correspondent, saying: “Cheering drug companies such as Pfizer, Glenmark, Abbott and Cipla, can't believe their luck.”

FDCs are used to improve patients' compliance in complicated courses of treatment, especially for conditions such as HIV, tuberculosis and malaria. Many of the popular drugs have been household names for several years, especially Pfizer's Corex cough syrup, Glaxo's Piriton expectorant, Reckitt Benckiser's D'Cold, Piramal's Saridon, Glenmark's Ascoril and Alex cough syrups, Abbott's Phensedyl cough syrup and Alembic's Glycodin cough syrup, as well as several anti-diabetes medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK